Latest News and Press Releases

Want to stay updated on the latest news?

Sign into Reader Account Create Reader Account

April 15, 2010 13:00 ET | Source: GlobeImmune

HCV-Arzneimittelkandidat GI-5005 von GlobeImmune verbessert anhaltendes virologisches Ansprechen (SVR) um 10 Prozent und hat damit das Potenzial zum ersten therapeutischen Impfstoff gegen HCV zu werden

LOUISVILLE, COLORADO--(Marketwire - April 15, 2010) - GlobeImmune, Inc. gab heute endgültige Ergebnisse einer Phase-2b-Studie zu GI-5005, dem in Entwicklung befindlichen...
March 17, 2010 16:12 ET | Source: GlobeImmune, Inc.

GlobeImmune Announces Presentations of GI-5005 Phase 2b Data at EASL 2010 Meeting

LOUISVILLE, CO--(Marketwire - March 17, 2010) - GlobeImmune Inc. today announced that three abstracts related to GI-5005, the company's hepatitis C (HCV) product candidate, have been accepted...
January 19, 2010 07:00 ET | Source: GlobeImmune, Inc.

GlobeImmune Announces $17.5 Million Series E Financing

LOUISVILLE, CO--(Marketwire - January 19, 2010) - GlobeImmune Inc., a company developing novel therapies for patients with cancer and infectious diseases, today announced a Series E Preferred Stock...
November 02, 2009 08:00 ET | Source: GlobeImmune, Inc.

GlobeImmune's Hepatitis C Therapeutic Vaccine Combined With Standard of Care Increases End of Treatment Response Rate by 15%

LOUISVILLE, CO--(Marketwire - November 2, 2009) - GlobeImmune Inc. will present Phase 2b data today at the 60th Annual Meeting of the American Association for the Study of Liver Diseases (AASLD)...
October 06, 2009 07:00 ET | Source: GlobeImmune, Inc.

GlobeImmune Announces Late-Breaker Presentation of GI-5005 Treatment Response Data at AASLD 2009 Meeting

LOUISVILLE, CO--(Marketwire - October 6, 2009) - GlobeImmune Inc. today announced that a late breaking abstract related to GI-5005, its investigational hepatitis C virus (HCV) product candidate, has...
May 15, 2009 07:30 ET | Source: GlobeImmune, Inc.

GlobeImmune and Celgene Corporation Announce Strategic Global Oncology Alliance

LOUISVILLE, CO and SUMMIT, NJ--(Marketwire - May 15, 2009) - GlobeImmune, Inc. and Celgene Corporation (NASDAQ: CELG) today announced a worldwide strategic collaboration focused on the discovery,...
April 24, 2009 01:59 ET | Source: GlobeImmune, Inc.

GlobeImmune's Hepatitis C Therapeutic Vaccine, GI-5005, Improves EVR Rates to 94 Percent in Phase 2 Clinical Trial

LOUISVILLE, CO--(Marketwire - April 24, 2009) - Twelve-week Phase 2 clinical trial data show that patients treated with GI-5005, GlobeImmune's targeted molecular immunogen (Tarmogen®) for the...
April 16, 2009 08:00 ET | Source: GlobeImmune, Inc.

GlobeImmune Initiates Phase 1 Clinical Trial With NCI in CEA Over-Expressing Cancers

LOUISVILLE, CO--(Marketwire - April 16, 2009) - GlobeImmune, Inc. today announced the initiation of a Phase 1 clinical trial to investigate the safety and tolerability of a new Tarmogen, GI-6207, in...
November 01, 2008 11:00 ET | Source: GlobeImmune, Inc.

GlobeImmune Hepatitis C Therapeutic Vaccine, GI-5005, Doubles Viral Clearance and Increases RVR Rates in Phase 2 Clinical Trial

LOUISVILLE, CO--(Marketwire - November 1, 2008) - Four-week Phase 2 clinical trial data show that GI-5005, GlobeImmune's hepatitis C virus (HCV) targeted molecular immunogen (Tarmogen®), doubled...
October 28, 2008 08:00 ET | Source: GlobeImmune Inc.

GlobeImmune HCV Phase 2 Four-week Clinical Trial Data for GI-5005 to Be Highlighted at the AASLD President's Press Conference

LOUISVILLE, CO--(Marketwire - October 28, 2008) - GlobeImmune Inc. today announced that four-week data from the on-going Phase 2 clinical trial for GI-5005, the Company's therapeutic vaccine...

keyboard_arrow_left Previous Page

Next Page keyboard_arrow_right